Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Myeloma

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Sep 25, 2022 9:19am

200 Views

Post# 34984875

RE:Myeloma

They said in last quarterly report that possibly two journal articles with Pelareorep and Myeloma were in the works as well. -----' Also November is World Pancreatic Awareness month and November 17,18 Depending on time zone is World Pancreatic Awareness day. --------- So our Golden Ticket might be arriving at exactly the right time to be cashed in. Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

<< Previous

Bullboard Posts

Next >>

Three high-conviction small-cap stocks across the risk spectrum